Optimizing the harvest of viral particles is important for the yield and purity of the final product.
Greg Swan
Advertisement
Greg Swan is business development manager, cell & gene therapies, at Avantor.
Articles by Greg Swan
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Everything to Know About Cell and Gene Therapy in 2025
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
